You are here

AstraZeneca flags return to drug sales growth in 2018

FILES-BRITAIN-PHARMACEUTICAL-HEALTH-EARNINGS-BUSINESS-ASTRAZENECA-092103.jpg
AstraZeneca expects to increase 2018 drug sales at a low single-digit per centage rate as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit.

[LONDON] AstraZeneca expects to increase 2018 drug sales at a low single-digit per centage rate as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit.

Product sales fell 5 per cent in 2017, the company said on Friday.

AstraZeneca has been through the drug industry's biggest ever cliff of patent expiries in recent years, which wiped out more than half of its sales, but chief executive Pascal Soriot said is was "steadily turning a corner".

Fourth-quarter profits came in better than analysts had expected, helped by one-off tax gains and growing revenue.

sentifi.com

Market voices on:

Revenue was boosted by "externalisation" deals, involving asset sales and collaborations, which some analysts have criticised as unduly flattering results. Such deals contributed US$2.3 billion in 2017 out of total revenue of US$22.5 billion.

AstraZeneca has some notable new product successes recently, with oncology pills Tagrisso and Lynparza both doing well and progress in other areas, including novel treatments for lung disorders.

Its heart drug Brilinta and Farxiga for diabetes have also both just breached the US$1 billion annual sales mark.

Still, the pace of its turnaround remains uncertain pending further clinical trial read-outs in the multibillion-dollar cancer immunotherapy market, where AstraZeneca is going head to head with industry giants like Merck & Co, Bristol-Myers Squibb and Roche.

AstraZeneca suffered the biggest daily fall in its shares last July, following disappointing initial results from a lung cancer trial dubbed Mystic. Since then the shares have rallied, helped by good news from two other studies.

Further data from the Mystic trial is due in the first half of this year.

Fourth-quarter core earnings per share (EPS), which exclude some items, increased 7 per cent to US$1.30 cents on revenue of US$5.78 billion. Analysts, on average, had forecast earnings of 84 US cents on revenue of US$5.46 billion, Thomson Reuters data showed.

For 2018, AstraZeneca expects core EPS of US$3.30 to US$3.50.

REUTERS

Most Read

No contents
Powered by GET.comGetCom